Disclaimer

The following slides are intended solely for private, educational use only. They may not be reprinted or distributed without the express written consent of BayCare and the presenting physician(s).
BayCare Cardiovascular Service Line Research

2018 C.A.S.E. Symposium
Cardiovascular, Arrhythmia, Surgery and Endovascular
Clinical Research Team

Centralized Services

- Study Selection Process
- Contracts, Budgets
- Institutional Review Board Submissions

Centralized management

Four Members of the Administrative Team including finance and regulatory support

Local Staff

Four Coordinators at Morton Plant
Two Coordinators at St. Joseph’s
One Coordinator at Mease Countryside, North Bay and Winter Haven

Over 200 patients participating in 20 enrolling studies and over 250 patients in follow up studies.
St. Joseph’s is beginning our first Phase 1 Study ArcticLine for recurrent atrial fibrillation

Morton Plant is the third highest enrolling site in the country for the DREAM STUDY: A Randomized, Sham–procedure–controlled Study of Allogeneic Mesenchymal Precursor Cells (rexlemestrocel-L) in Patients with Chronic Heart Failure Due to Left Ventricular Systolic Dysfunction

Morton Plant has consented the highest number of patients in the CardiAMP Study: A Randomized Pivotal Trial of Autologous Bone Marrow Mononuclear Cells in Patients with Post Myocardial Infarction Heart Failure

Morton Plant and North Bay BMG Cardiology participated in the landmark Compass trial Rivaroxaban 2.5 bid + ASA which showed a significant reduction in MACE in patients with chronic CAD or PVD compared to ASA alone
# Cardiovascular Clinical Research

<table>
<thead>
<tr>
<th>Enrolling:</th>
<th>MPH</th>
<th>MCS</th>
<th>NB</th>
<th>SJH</th>
<th>WHH</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADAPT RESPONSE</td>
<td>X</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>APOLO</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CALM 2</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>CARDIAMP</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CONNECT HF</td>
<td></td>
<td></td>
<td>X</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>ECLIPSE</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EMPEROR (2)</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>EVOLUT</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NSTEMI</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>PIONEER</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>PORTICO</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PPP/SLS/PSR</td>
<td>X</td>
<td></td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>REFLECT</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>REX REVEAL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>SMART CRT</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>STOP AF</td>
<td>?</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>TEVA</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>VICTORIA</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>XIENCE 90</td>
<td>X</td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
</tr>
</tbody>
</table>

BayCare 2018 C.A.S.E. Symposium
CHF AND STEM TRIALS

LESLIE MILLER, MD
Medical Director,
Heart Function Clinic at Morton Plant Hospital
STEM CELL TRIALS

**TEVA –DREAM:** A Double-blind, Randomized, Sham-procedure-controlled, Parallel-group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (rexlemestrocel-L) in Patients with Chronic Heart Failure Due to Left Ventricular Systolic Dysfunction of Either Ischemic or Nonischemic Etiology

**CardiAMP:** Randomized Controlled Pivotal Trial of Autologous Bone Marrow Mononuclear Cells Using the CardiAMP Cell Therapy system in Patients with Post Myocardial Infarction Heart Failure

**NSTEMI:** A double-blind, sham-controlled clinical study to evaluate the safety and feasibility of AMI MultiStem therapy in subjects who have had a heart attack (Non-ST elevation MI)
CONGESTIVE HEART FAILURE TRIALS

**VICTORIA**: A randomized parallel-group, placebo-controlled, double-blind, event driven, multi-center pivotal phase III clinical outcome trial of efficacy and safety of the oral sGC stimulator Vericiguat in subjects with heart failure with reduced ejection fraction (HFrEF)

**EMPEROR Trials**: Phase III randomized, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic heart failure with either reduced (HFrEF) or preserved (HRpEF) ejection fraction

**CONNECT HF**: A large-scale, pragmatic, cluster-randomized clinical trial to evaluate the effect of 2 quality improvement (QI) initiatives compared with usual care on heart failure (HF) outcomes and HF quality of care metrics in the year following discharge for participants hospitalized with acute HF and reduced ejection fraction (EF).

**AdaptResponse**: A prospective, randomized, controlled, interventional, single-blinded, multi-center, post-market, global Cardiac Resynchronization Therapy (CRT) in heart failure (HF) clinical study

**SMART CRT**: Strategic Management to Optimize Response to Cardiac Resynchronization Therapy
Clearwater Cardiovascular Consultants Clinical Research Site

Research Site since 1991

- > 150 Drug, Device and Registry Sponsored Trials
- > 5000 patient/subjects enrolled

CCC Research Team:
- 21 Physician Investigators
- 7 Clinical Research Coordinators
- Director, Regulatory Coordinator & several Research Assistants

Research Steering Committee
- 7 Physicians & Director meet every 2-3 months
Clearwater Cardiovascular Consultants Clinical Research Site

Subject Visits conducted at

3 CCC Clinics in Clearwater, Largo & Safety Harbor & CCC Cath Lab
Morton Plant Hospital & Mease Countryside Hospital

Current Study Portfolio

Enrolling 16
Follow Up 14
Startup / Closeout 5 / 7

Top enroller in many Global Trials

Twilight  Mount Sinai & Astra Zeneca  Absorb III & IV  Abbott Vascular
Evolve Short DAPT  Boston Scientific  Wrap It  Medtronic
### List of Currently Enrolling Studies

<table>
<thead>
<tr>
<th>Study</th>
<th>Condition</th>
<th>Intervention</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Aegis II</strong></td>
<td>Acute ACS</td>
<td>Post ACS infusion CSL 112_3001 or placebo x 4 to reduce future CV events.</td>
<td></td>
</tr>
<tr>
<td><strong>Beat HF</strong></td>
<td>Chronic CHF</td>
<td>Baroreflex activation therapy device for HF related symptoms</td>
<td></td>
</tr>
<tr>
<td><strong>Dal-Gene</strong></td>
<td>AA Gene - hyperlipidemia</td>
<td>Evaluate Dalcetrapib in AA genotype patients to reduce Major CV Events</td>
<td></td>
</tr>
<tr>
<td><strong>Esperion Statin Intolerant</strong></td>
<td></td>
<td>Evaluate Bempedoic Acid vs. Placebo with statin intolerant patients</td>
<td></td>
</tr>
<tr>
<td><strong>Invested High Risk CV - Flu Vaccine</strong></td>
<td></td>
<td>Standard dose vaccine vs high dose vaccine for high risk CV patients to reduce future CV events</td>
<td></td>
</tr>
<tr>
<td><strong>Onyx PAS</strong></td>
<td>Resolute ONYX Stent</td>
<td>Post approval registry to assess the continued safety and efficacy of the Resolute Onyx™ stent</td>
<td></td>
</tr>
<tr>
<td><strong>Optimize</strong></td>
<td>Invest. Coronary Stent</td>
<td>Inv. Svelte DES-IDS or DES-RX Sirolmus Eluting Stent Systems Vs. Xience or Promus</td>
<td></td>
</tr>
<tr>
<td><strong>Optimize IVUS</strong></td>
<td>Invest. Coronary Stent</td>
<td>Inv. Svelte DES-IDS or DES-RX Sirolmus Eluting Stent Systems Vs. Xience or Promus. IVUS @ base and 1 yr</td>
<td></td>
</tr>
<tr>
<td><strong>Pioneer III</strong></td>
<td>Invest. Coronary Stent</td>
<td>Inv. BuMA Supreme Biodegradable Drug Coated Coronary Stent vs commercially available DES.</td>
<td></td>
</tr>
<tr>
<td><strong>Paradise</strong></td>
<td>New CHF</td>
<td>Acute MI w/ LV systolic dysfunction (LVEF ≤40%); Entresto vs Ramipril to reduce future CV events</td>
<td></td>
</tr>
<tr>
<td><strong>Prominent High TG</strong></td>
<td></td>
<td>Pemafibrate BID vs. Placebo with Diabetic patients who have TG ≥200 and &lt;500 with CAD or PAD</td>
<td></td>
</tr>
<tr>
<td><strong>PSR Medtronic Device implant</strong></td>
<td>Medtronic Device implant</td>
<td>Post Market Registry - Pacing/Defib/Left-Heart Leads. Medical Record Review Only</td>
<td></td>
</tr>
<tr>
<td><strong>Transcend</strong></td>
<td>Invest. DCB</td>
<td>Surveil DCB- Paclitaxel Drug Eluting Peripheral Balloon vs Medtronic IN.PACT DCB - SFA stenosis</td>
<td></td>
</tr>
<tr>
<td><strong>Victoria</strong></td>
<td>Chronic CHF</td>
<td>Chronic CHF with EF &lt;45%; MK-1242 (Vericiguat) vs. placebo, on a background of standard of care.</td>
<td></td>
</tr>
<tr>
<td><strong>Victoria Registry</strong></td>
<td>Chronic CHF</td>
<td>Characterizing patients hospitalized for HF decompensation during prescreening for VICTORIA Study</td>
<td></td>
</tr>
<tr>
<td><strong>Xience 90</strong></td>
<td>90 day DAPT</td>
<td>90 day DAPT for patients at high risk for bleeding after a PCI with Xience Stent.</td>
<td></td>
</tr>
</tbody>
</table>
Dal-Gene DalCor Pharma UK Ltd

- Use of dalcetrapib to reduce cardiovascular events in subjects with a documented recent ACS and the AA genotype
- Dalcetrapib is a CETP inhibitor with potential to increase HDL
- Inclusion: acute MI, AA genotype

PARADISE Novartis

- Entresto vs. Ramipril to reduce HF or CV events
- Entresto was approved for chronic CHF in 2015
- Inclusion: acute HF, EF < 40 must enroll within 7 days of event
**Optimize RCS**

- Svelte DE-S-IDS or DE-S-RX Sirolimus Eluting Stent Systems Vs. Xience or Promus
- Direct Stenting Approach
- Stent system already approved in Europe

**AEGIS II**

- Post ACS infusion CSL 112 or placebo x 4 to reduce future CV events.
- Inclusion: acute MI  **Must enroll within 5 days of event**
- CSL 112 is a novel IV formulation of apoA-1
Thank You!

Michele Cameron, RN, BSN, MBA
Director of Clinical Research
cameronm@cccheart.com
www.cccheart.com
INTERVENTIONAL CARDIOVASCULAR TRIALS

Lang Lin, MD
Interventional Cardiologist,
Center for Advanced Valve and Structural Heart Care
at Morton Plant Hospital
Enrolling Clinical Trials at BayCare

INTERVENTIONAL

**ECLIPSE:** Evaluation of Treatment Strategies for Severe Calcific Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplasty Technique Prior to Implantation of Drug-Eluting Stents (ECLIPSE)

**Reveal:** To evaluate the safety and effectiveness of the Revolution™ Peripheral Atherectomy System in the treatment of infrainguinal lower extremity peripheral arterial occlusive disease

**STOP AF:** The purpose of the study is to provide data demonstrating the safety and effectiveness of the Arctic Front Advance™ Cardiac CryoAblation Catheter for the treatment of recurrent symptomatic paroxysmal AF, without the requirement that the subjects be drug refractory.

**XIENCE 90:** A prospective, single arm, multi-center, open label, non-randomized trial to evaluate the safety of 3 month DAPT in HBR (high bleeding risk) subjects undergoing PCI with Xience.

**ArticLine Feasibility Study:** Phase I trial to collect preliminary safety and effectiveness data on the ArticLine Catheter
STRUCTURAL HEART AND VALVE CENTER

Joshua Rovin, MD
Medical Director,
Center for Advanced Valve and Structural Heart Care
at Morton Plant Hospital
Evolut R: To demonstrate that the safety and effectiveness of the Medtronic TAVR system as measured by rates of all-cause mortality or disabling stroke at two years is noninferior to SAVR in the treatment of severe aortic stenosis in subjects who have a low predicted risk of operative mortality for SAVR (Low Risk).

There is now a Continued Access Study as well as use of Evolut R for Bicuspid valves.

Portico: Further assess the performance and safety profile of the commercially available Portico Valve implanted, using the Delivery System and the Loading System, in patients with severe symptomatic aortic stenosis (High Risk).

Reflect: A Randomized Evaluation of the TriGuard HDH Cerebral Embolic Protection Device and the TriGuard 3 Cerebral Embolic Protection Device to Reduce the Impact of Cerebral Embolic Lesions after Transcatheter Aortic valve Implantation.

APOLLO: Transcatheter Mitral Valve Replacement with the Medtronic Intrepid TMVR System in patients with severe symptomatic mitral regurgitation.